We’re doubling down on what we do best—accessing our vast experience to help solve the healthcare community’s biggest challenges, working with urgency, as we innovate and ensure our front lines have the innovative solutions and tools they need to address this pandemic and enhance patient care, as they impact lives around the world.
Delivering a path out of the crisis together

BD has mobilized and our devices are set to deliver the COVID-19 vaccine to the world
In the midst of this global pandemic, we understand the responsibility we carry as the world’s largest manufacturer of injection devices. This position of leadership is why we responded to the crisis early—rapidly scaling up our manufacturing operations. We’re here now, delivering a path out of this crisis, so we can enable healthcare providers to deliver the best possible patient care, which includes meeting the critical need for vaccinations.
BD has already committed 2 billion injection devices to countries and nongovernmental organizations around the world*
* Publicly confirmed as of June 2021
The journey of a vaccine delivery device

BD has been by the side of vaccine developers and healthcare providers for decades, ensuring the availability and safe administration of vaccines from polio to the seasonal flu.

BD is partnering with governments and NGOs to ensure we deliver the right type of injection device in the right quantities to the right place at the right time.

BD has accelerated production of needles and syringes to ensure continuity of supply to our customers, while prioritizing patient care and meeting the requests for heightened vaccination needs.
-
Syringe and needle technology that makes a difference
Learn More
-
Our responsibility in a time of crisis
Learn More
-
BD COVID-19 response—supply continuity plan
Learn More
-
Scaling up your COVID-19 response: Options for optimising drug availability and safety
Learn More
-
Product training, education and clinical resources
Learn More
-
Increasing access to COVID-19 testing with our BD Veritor™ Plus System**
Learn More
-
COVID-19 Insights & Analytics
Learn More
-
COVID-19 on-demand webinars
Learn More
-
Vascular access and medication delivery COVID-19 response efforts
Learn More
-
July 8, 2020—How BD is preparing for global COVID-19 vaccination campaigns
Learn More
-
Nov. 5, 2020—Pellets to pallets to patients: delivering injection devices for COVID-19 vaccinations
Learn More
-
June 8, 2021—BD Hits 2 Billion Injection Device Milestone in Support of Global COVID-19 Vaccination Efforts
Learn More
-
July 8, 2020—BD Partners with U.S. Government on $70 Million Manufacturing Infrastructure Project for Mass...
Learn More
-
CDC: COVID-19 Vaccination Training Programs and Reference Materials
Learn More
-
COVID-19 Vaccination Program interim playbook for Jurisdiction
Learn More
-
Product Information Guide for COVID-19 Vaccines and Associated Products
Learn More
-
Strategies for Sharps Disposal Container Use During Supply Shortages
Learn More
-
Safe and Proper Sharps Disposal During the COVID-19 Mass Vaccination Campaign
Learn More
-
CDC: COVID-19 Vaccination Home
Learn More
** This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories.
This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
BD-22503 (06/21)